243 related articles for article (PubMed ID: 31213907)
1. Impact of
Igawa S; Ono T; Kasajima M; Ishihara M; Hiyoshi Y; Kusuhara S; Nishinarita N; Fukui T; Kubota M; Sasaki J; Hisashi M; Yokoba M; Katagiri M; Naoki K
Cancer Manag Res; 2019; 11():4883-4892. PubMed ID: 31213907
[No Abstract] [Full Text] [Related]
2.
Zheng Q; Huang Y; Zhao H; Yang Y; Hong S; Hou X; Zhao Y; Ma Y; Zhou T; Zhang Y; Fang W; Zhang L
Transl Lung Cancer Res; 2020 Jun; 9(3):471-483. PubMed ID: 32676311
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
Zheng Z; Jin X; Lin B; Su H; Chen H; Fei S; Zhao L; Deng X; Xie D; Xie C
J Cancer; 2017; 8(4):597-605. PubMed ID: 28367239
[No Abstract] [Full Text] [Related]
4. Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study.
Peng D; Shan D; Dai C; Li J; Wang Z; Huang Z; Peng R; Zhao P; Ma X
Cancer Manag Res; 2021; 13():2033-2039. PubMed ID: 33679141
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.
Yoshimura A; Yamada T; Okura N; Takeda T; Hirose K; Kubota Y; Shiotsu S; Hiranuma O; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875919
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib
Gilardone S; Thapa R; Laborde J; Shafique M; Saltos A; Creelan B; Tanvetyanon T; Chiappori A; Simon G; Haura EB; Gray JE; Chen DT; Melzer D; Pellini B
J Thorac Dis; 2023 Nov; 15(11):6115-6125. PubMed ID: 38090314
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
8. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W
Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
[TBL] [Abstract][Full Text] [Related]
10. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (
Xu Z; Hao X; Wang Q; Wang J; Yang K; Wang S; Teng F; Li J; Xing P
Cancer Manag Res; 2022; 14():863-873. PubMed ID: 35256860
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
Saad N; Poudel A; Basnet A; Gajra A
Onco Targets Ther; 2017; 10():1757-1766. PubMed ID: 28367058
[TBL] [Abstract][Full Text] [Related]
13. EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Choi YW; Jeon SY; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Koh YW; Han JH; Sheen SS
Am J Clin Oncol; 2018 Apr; 41(4):385-390. PubMed ID: 26967328
[TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
[TBL] [Abstract][Full Text] [Related]
15. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis.
Liu Y; Ren Z; Wang J; Zhang S
Thorac Cancer; 2016 Jul; 7(4):406-14. PubMed ID: 27385982
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes of EGFR-TKI with or without locoregional brain therapy in advanced EGFR-mutant non-small cell lung cancer patients with brain metastases.
Linh DM; Thinh TH; Hieu NV; Duc NM
Contemp Oncol (Pozn); 2023; 27(2):71-79. PubMed ID: 37794989
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib - effective treatment of NSCLC with activating
Skrzypski M; Szymanowska-Narloch A; Dziadziuszko R
Contemp Oncol (Pozn); 2017; 21(3):254-258. PubMed ID: 29180936
[TBL] [Abstract][Full Text] [Related]
20. Impact of Weight Loss at Presentation on Survival in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) Sensitive Mutant Advanced Non-small Cell Lung Cancer (NSCLC) Treated with First-line EGFR-TKI.
Lin L; Zhao J; Hu J; Huang F; Han J; He Y; Cao X
J Cancer; 2018; 9(3):528-534. PubMed ID: 29483958
[No Abstract] [Full Text] [Related]
[Next] [New Search]